{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:24:45Z","timestamp":1763036685978},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["neurology.org"],"crossmark-restriction":true},"short-container-title":["Neurology"],"published-print":{"date-parts":[[1995,3]]},"DOI":"10.1212\/wnl.45.3.506","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T13:14:59Z","timestamp":1336914899000},"page":"506-508","update-policy":"http:\/\/dx.doi.org\/10.1212\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":70,"title":["Comparison of Therapeutic Efficacies of Type A and F Botulinum Toxins for Blepharospasm"],"prefix":"10.1212","volume":"45","author":[{"given":"T.","family":"Mezaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Kohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. F.","family":"Brin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101033240101"},{"key":"e_1_3_1_3_2","first-page":"1","volume":"48","year":"1991","unstructured":"Clinical use of botulinum toxin. National Institute of Health Consensus Development Conference Statement, November 12-14, 1990. Arch Neurol 1991;48:1294-1298.","journal-title":"Arch Neurol"},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","unstructured":"Brin MF Blitzer A Stewart C et al. Disorders with excessive muscle contraction: candidates for treatment with intramuscular botulinum toxin ('Botox'). In: DasGupta BR ed. Botulinum and tetanus neurotoxins: neurotransmission and biomedical aspects. New York: Plenum Press 1993:559-576.","DOI":"10.1007\/978-1-4757-9542-4_62"},{"key":"e_1_3_1_5_2","first-page":"4","volume":"12","year":"1993","unstructured":"Blasi J, Chapman ER, Yamasaki S, Binz T, Niemann H, Jahn R. Botulinum neurotoxin-Cl blocks neurotransmitter release by means of cleaving HPC-I\/syntaxin. EMBO J 1993;12:4821-4828.","journal-title":"EMBO J"},{"key":"e_1_3_1_6_2","first-page":"1","volume":"365","year":"1993","unstructured":"Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993;365:160-163.","journal-title":"Nature"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","unstructured":"Schiavo G Shone CC Rosetto O Alexander FC Montecucco C. Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP\/synaptobrevin. J Biol Chem 1993;268: 11516-11519.","DOI":"10.1016\/S0021-9258(19)50230-7"},{"key":"e_1_3_1_8_2","first-page":"1","volume":"48","year":"1991","unstructured":"Jankovic J, Schwartz KS. Clinical correlates of response to botulinum toxin injections. Arch Neurol 1991;48:1253-1256.","journal-title":"Arch Neurol"},{"key":"e_1_3_1_9_2","first-page":"1","volume":"43","year":"1993","unstructured":"Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 1993;43:1715-1718.","journal-title":"Neurology"},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","unstructured":"Greene P Fahn S. Development of antibodies to botulinum toxin type A in patients with torticollis treated with injections of botulinum toxin type A. In: DasGupta BR ed. Botulinum and tetanus neurotoxins: neurotransmission and biomedical aspects. New York: Plenum Press 1993:651-654.","DOI":"10.1007\/978-1-4757-9542-4_72"},{"key":"e_1_3_1_11_2","first-page":"4","volume":"8","year":"1993","unstructured":"Greene P, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 1993;8:479-483.","journal-title":"Mov Disord"},{"key":"e_1_3_1_12_2","first-page":"3","volume":"326","year":"1992","unstructured":"Ludlow CL, Hallett M, Rhew K, et al. Therapeutic use of type F botulinum toxin. N Engl J Med 1992;326:349-350.","journal-title":"N Engl J Med"},{"key":"e_1_3_1_13_2","unstructured":"Fahn S List T Moskowitz CB et al. Double-blind controlled study of botulinum toxin for blepharospasm (abstract). Neurology 1985;35(suppl 1):271."},{"key":"e_1_3_1_14_2","first-page":"4","volume":"150","year":"1984","unstructured":"Hathaway CH, Snyder JD, Seals JE, Edell TA, Lewis GE. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J Infect Dis 1984;150:407-412.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_15_2","first-page":"6","volume":"53","year":"1990","unstructured":"Jankovic J, Schwartz K, Donovan DT. Botulinum treatment of cranio-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990;53:633-639.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","unstructured":"Kauffman JA Way JF Jr Siegel LS Sellin LC. Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction. Toxicol Appl Pharmacol 1985;79: 211-217.","DOI":"10.1016\/0041-008X(85)90342-4"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.45.3.506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T16:04:59Z","timestamp":1711641899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.45.3.506"}},"subtitle":["A double-blind, controlled study"],"short-title":[],"issued":{"date-parts":[[1995,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1995,3]]}},"alternative-id":["10.1212\/WNL.45.3.506"],"URL":"https:\/\/doi.org\/10.1212\/wnl.45.3.506","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,3]]}}}